Cassandra O. Blew

Cassandra O. Blew

Auto-generated profile, based on publicly available information

Cassandra O. Blew

Laboratory of Behavioral Neuroscience, National Institute on Aging, Intramural Research Program, Baltimore, MD 21224, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2026 in Science Advances
Verified
Journal Article
Open access
CBCassandra O. Blew
Cassandra O. Blew
MDMichael R. Duggan
Michael R. Duggan
DTDimitrios Tsitsipatis
Dimitrios Tsitsipatis
GGGabriela T. Gomez
Gabriela T. Gomez
ZRZulema Rodriguez-Hernandez
Zulema Rodriguez-Hernandez
KWKeenan A. Walker
Keenan A. Walker
Growth/differentiation factor–15 (GDF15) is a secreted cytokine strongly associated with dementia risk. However, the extent to which GDF15 represents a biomarker and driver of dementia risk remains unclear. Across multiple cohorts, we demonstrated that plasma GDF15 is associated with greater dementia risk over 15- to 25-year follow-up periods when measured in midlife, with stronger associations observed for vascular, compared to Alzheimer’s disease (AD), dementia. Two-sample Mendelian randomization supported plasma GDF15’s mechanistic role in AD and related dementias, while cohort studies linked it to cerebral small vessel disease, neurodegeneration, phosphorylated tau, and a cerebrospinal fluid proteomic signature indicative of neuroimmune activation. Exposure of cultured myeloid cells to recombinant GDF15 altered biological pathways that we subsequently demonstrated are predictive of dementia risk, including interferon/antiviral responses. These findings support circulating GDF15’s role as an early biomarker—particularly for vascular dementia and neuroinflammation—and identify the mechanisms by which it may drive dementia risk.

21 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CBCassandra O. Blew
Cassandra O. Blew
MDMichael R. Duggan
Michael R. Duggan
DTDimitrios Tsitsipatis
Dimitrios Tsitsipatis
GGGabriella T. Gomez
Gabriella T. Gomez
ZHZulema Rodriguez Hernandez
Zulema Rodriguez Hernandez
KWKeenan A. Walker
Keenan A. Walker
Growth/differentiation factor-15 (GDF15) is a secreted peptide hormone and cytokine that is strongly associated with dementia risk. However, the extent to which plasma GDF15 represents a biomarker and driver of dementia risk remains unclear. Across multiple cohorts, we demonstrated that plasma GDF15 is associated with greater dementia risk over 15-to 25-year follow-up periods when measured in midlife, with stronger associations observed for vascular dementia compared to Alzheimer’s disease (AD). Two-sample Mendelian randomization supported plasma GDF15’s mechanistic role in AD and related dementias, while cohort studies linked it to cerebral small vessel disease, diffuse neurodegeneration, phosphorylated tau, and a cerebrospinal fluid proteomic signature indicative of neuro-immune activation. Exposure of cultured myeloid cells to recombinant GDF15 altered biological pathways that we subsequently demonstrated are predictive of dementia risk, including interferon/antiviral responses, pyruvate metabolism, and scavenging of heme. These findings support circulating GDF15’s role as an early biomarker – particularly for vascular dementia and neuroinflammation – and identify the mechanisms by which it may drive dementia risk.

1 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
KWKeenan A. Walker
Keenan A. Walker
CBCassandra Blew
Cassandra Blew
MDMichael R. Duggan
Michael R. Duggan
CJCassie Joynes
Cassie Joynes
GGGabriela T. Gomez
Gabriela T. Gomez
PSPascal Schlosser
Pascal Schlosser
The rapid expansion of plasma proteomic data and protein quantitative trait loci (pQTLs) provides an opportunity to identify genes that confer disease risk through their effect on plasma protein abundance. We conducted an Alzheimer’s disease (AD) proteome-wide association study (PWAS) integrating publicly available plasma cis-pQTL data (1348 European American and 1385 African American genetically determined protein models) with AD dementia GWAS summary statistics. Whereas the African American PWAS identified one candidate [apolipoprotein E (APOE)] and multiple suggestive genes, the European American PWAS identified 18 genes with putative causal relationships with AD through cis regulation of plasma protein abundance. Thirteen of these candidate genes were additionally supported by colocalization and complementary causal-inference analyses such as summary data–based Mendelian randomization. Four of these proteins were not previously detected in AD GWAS [complement decay-accelerating factor (CD55), leukocyte immunoglobulin-like receptor B1 (LILRB1), scavenger receptor class A member 5 (SCARA5), and signal regulatory protein alpha (SIRPA)]. A subset of candidate gene-associated proteins was associated with 8- and 20-year dementia risk, markers of AD pathology, and a CSF proteomic signature enriched for immune and metabolic processes. Putative causal proteins were enriched for adaptive (lymphocyte-mediated) immunity and, compared with GWAS candidates, showed less enrichment for synaptic and amyloid regulatory processes. LILRB1 and SIRPA, two immunoregulatory proteins not previously implicated in AD GWAS, showed the strongest mechanistic link to AD in the European American PWAS. These results shed additional light on AD etiology and enable the prioritization of potential AD therapeutic targets in peripheral circulation.